340 related articles for article (PubMed ID: 30926634)
1. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
3. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
8. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
9. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
10. STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
Okemoto K; Wagner B; Meisen H; Haseley A; Kaur B; Chiocca EA
PLoS One; 2013; 8(8):e71932. PubMed ID: 23936533
[TBL] [Abstract][Full Text] [Related]
11. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.
Delwar ZM; Kuo Y; Wen YH; Rennie PS; Jia W
Cancer Res; 2018 Feb; 78(3):718-730. PubMed ID: 29118089
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition.
Otani Y; Yoo JY; Chao S; Liu J; Jaime-Ramirez AC; Lee TJ; Hurwitz B; Yan Y; Dai H; Glorioso JC; Caligiuri MA; Yu J; Kaur B
Clin Cancer Res; 2020 May; 26(10):2381-2392. PubMed ID: 32139403
[TBL] [Abstract][Full Text] [Related]
14. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
[TBL] [Abstract][Full Text] [Related]
16. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
[TBL] [Abstract][Full Text] [Related]
18. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
[TBL] [Abstract][Full Text] [Related]
19. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
